Equity Issuances

Seer, Inc. issued common stock.

“At the close of business on December 9, 2025, each outstanding share of Class B Common Stock, par value $0.00001 per share (the “Class B Common Stock”), of Seer, Inc. (the “Company”), automatically converted (the “Conversion”) into one share of the Company’s Class A Common Stock”

Momentus Inc. issued 7,293,087 shares of Common Stock of warrant to Holder for exercise of Existing Warrants to purchase 4,862,058 shares of the Common Stock at an exercise price of $0.77 per share.

“share (the “Common Stock”), of the Company. Pursuant to the Inducement Agreement, the Holder agreed to exercise for cash on December 9, 2025, its Existing Warrants to purchase 4,862,058 shares of the Common Stock at an exercise price of $0.77 per share, which was the closing price of the Common Stock on the Nasdaq Capital Market on December 9, 2025. Prior to”

Interactive Strength, Inc. issued 115,000 shares of Common Stock of common stock to Vertical Investors, LLC for $5.50 per Exchange Share.

“to reduce the Loan Amount by $632,500 in exchange for the issuance of 115,000 shares of Common Stock (the “Exchange Shares”) to the Lender at a price per Exchange Share of $5.50. The Exchange Shares will not contain a restrictive legend under the Securities Act of 1933, as amended (the “Securities Act”). As a result of this transaction, the outstanding”

CXApp Inc. issued 3,266,615 shares of common stock to Avondale Capital, LLC for $0.348985 per share.

“CXApp Inc. (the “Company”) issued an aggregate of 3,266,615 shares of common stock to Avondale Capital, LLC (“Avondale”) under a Pre-Paid Purchase #1, dated as of March 26, 2025, which was entered into pursuant to the Securities Purchase Agreement, dated as of March 26, 2025, by and between the Company and Avondale. The shares of common stock were issued on December 9, 2025 and December 10, 2025, at a price of $0.348985 per share.”

CDT Equity Inc. issued 3,685,815 pre-funded warrants of warrant to Corvus Capital Limited.

“3,685,815 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock”

CDT Equity Inc. issued 224,800 shares of common stock of common stock to Corvus Capital Limited for $7,000,000 that was satisfied through the issuance.

“CPL, including the potential liability associated with the litigation, to Corvus, a wholly-owned subsidiary of the Company’s Chief Executive Officer for a settlement amount of $7,000,000 that was satisfied through the issuance of the CDT Shares and Pre-Funded Warrants. Prior to the execution of the Agreement, CPL transferred its shareholding in its wholly-owned”

Karbon Capital Partners Corp. issued 890,000 Private Placement Units of unit to Sponsor for $10.00 per Private Placement Unit.

“simultaneously with the closing of the IPO, pursuant to the Private Placement Unit Purchase Agreement, the Company consummated the private placement of 890,000 Private Placement Units at a price of $10.00 per Private Placement Unit, generating total proceeds of $8,900,000”

Enveric Biosciences, Inc. issued up to 426,390 shares of warrant to certain institutional investors for $7.05 per share exercise price and $0.125 per share purchase price.

“(collectively, the “Existing Warrants”). Pursuant to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $7.05 per share and pay a purchase price of $0.125 per share in consideration for the Company’s agreement to issue in a private placement (x) new Series E Common Stock Purchase Warrants”

Creative Media & Community Trust Corp issued 94,884 shares of Common Stock of common stock for redemption of 28,510 shares of Series A Preferred Stock, including accrued and unpaid dividends, conversion price $7.58 per share.

“On December 11, 2025, the Company issued 94,884 shares of Common Stock in respect of redemptions of the Company’s Series A Preferred Stock, par value $0.001 (the “Series A Preferred Stock”), in lieu of cash payment for the redemption of 28,510 shares of Series A Preferred Stock, including accrued and unpaid dividends.”

Creative Media & Community Trust Corp issued 62,895 shares of Common Stock of common stock for redemption of 20,238 shares of Series A1 Preferred Stock, including accrued and unpaid dividends, conversion price $7.58 per share.

“On December 11, 2025, Creative Media & Community Trust Corporation (the “Company”) issued 62,895 shares of Common Stock in respect of redemptions of the Company’s Series A1 Preferred Stock, par value $0.001 (the “Series A1 Preferred Stock”), in lieu of cash payment for the redemption of 20,238 shares of Series A1 Preferred Stock, including accrued and unpaid dividends.”

Worksport Ltd issued up to 3,840,421 shares of Common Stock of warrant to a certain holder (the "Holder") of existing warrants for reduced exercise price of $2.90 per share.

“the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of 2,194,526 shares of Common Stock at a reduced exercise price of $2.90 per share, in consideration for the Company’s agreement to issue new warrants (the “Inducement Warrants”) having terms as described below, to purchase up to 3,840,421 shares of”

CEMTREX INC issued 2,234,247 Series B Warrants of warrant for $5.5 million proceeds.

“2,234,247 shares of common shares upon the exercise of 2,234,247 Series B Warrants. The Company received $5.5 million proceeds on the exercises of the Series B Warrants.”

CEMTREX INC issued 9,981 Series A Warrants of warrant.

“The Company also issued 29,943 shares of common stock upon the exercise of 9,981 Series A Warrants”

CEMTREX INC issued 2,500,609 shares of common stock to certain lenders for $6,084,000 of debt.

“On December 8, 2025, the company issued 2,500,609 shares of its common stock pursuant to exchange agreement to satisfy $6,084,000 of debt with certain lenders.”

CoreWeave, Inc. issued convertible note to qualified institutional buyers for $2,587,500,000 aggregate principal amount.

“on December 11, 2025, CoreWeave, Inc. (“CoreWeave”) completed its previously announced private offering of $2,587,500,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”) to persons reasonably believed to be qualified institutional buyers”

Valion Bio, Inc. issued preferred stock.

“the Company’s sale of shares of Series C Preferred Stock and below in Item 5.03 regarding the designation of the Series C Preferred Stock and the preferences, rights and limitations applicable thereto”

Valion Bio, Inc. issued up to an aggregate of 4,553,213 shares of the Company’s common stock of warrant to 3i for $16,253,147.10 aggregate purchase price.

“provide similar services to other clients in the future. Pursuant to the APA, as consideration for the Acquired Assets, the Company (on behalf of VBI) paid the Collateral Agent $16,253,147.10 in cash at closing of the Acquisition. Consistent with customary practices in a sale under Article 9, the APA does not contain representations, warranties, covenants or”

Valion Bio, Inc. issued convertible note to 3i for $16,253,147.10 aggregate purchase price.

“the Company agreed to issue, in a private placement, upon the satisfaction of certain conditions specified in the Note Purchase Agreement, a senior secured convertible note (the “Note”) in the principal amount of $16,253,147.10”

CID Holdco, Inc. issued up to 230,770 shares of common stock of warrant to J.J. Astor & Co. for exercise price of $1.69 per share.

“In connection with the Loan Agreement, the Company issued the Lender a warrant (the “Initial Lender Warrant and together with any Additional Lender Warrants, the “Lender Warrants”) to purchase up to 230,770 shares of common stock, par value $0.0001 per share, of the Company (the “Company”) at an exercise price of $1.69 per share, subject to certain adjustments.”

CID Holdco, Inc. issued convertible note to J.J. Astor & Co. for $1,840,000 funded by the Lender at the funding date after deducting the Lender's origination fees and expenses from the amount of the Initial Loan.

“On December 5, 2025, CID Holdco, Inc. (the “Company”) entered into a Loan Agreement with J.J. Astor & Co., a Utah corporation (including its successors and assigns, the “Lender”), pursuant to which the Company may borrow up to $5,000,000 in four tranches comprised of an initial $2,000,000 tranche (the “Initial Loan”) borrowed on the initial funding date of December 5, 2025 (the “Initial Funding Date”) and up to three additional tranches of $1,000,000 each (the “Additional Loans” and together with the Initial Loan, the “Loans”). The Initial Loan is evidenced by a Senior Secured Convertible Note issued to the Lender for an original principal amount of $2,600,000 (the “Initial Note”), of which $1,840,000 was funded by the Lender at the funding date after deducting the Lender’s origination fees and expenses from the amount of the Initial Loan.”

Daedalus Special Acquisition Corp. issued 685,000 units of unit to the Sponsor and BTIG for $10.00 per Private Unit, generating total proceeds of $6,850,000.

“Simultaneously with the closing of the IPO, the Company consummated a private placement (the “Private Placement”) of an aggregate of 685,000 units (the “Private Units”) to the Sponsor and BTIG, at a price of $10.00 per Private Unit, generating total proceeds of $6,850,000.”

Sarepta Therapeutics, Inc. issued approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 of convertible note to certain holders of its 1.25% Convertible Senior Notes due 2027, including the Michael A. Chambers Living Trust for approximately $291.4 million in aggregate principal amount of Existing Convertible Notes and approximately $31.6 million in cash.

“a member of the Company’s board of directors. Under the terms of the Exchange Agreements, the holders party thereto have agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due”

CHINA PHARMA HOLDINGS, INC. issued 3,500,000 restricted shares of Common Stock of common stock to Lijie Tang for $6.3 million, $1.80 per share.

“research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.3 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), at $1.80 per share. transfer price as contemplated by the”

BIMINI CAPITAL MANAGEMENT, INC. issued unit.

“The First Amendment extends the expiration date of the Rights (as defined in the Rights Agreement) until December 21, 2030. The First Amendment also increases the Purchase Price (as defined in the Rights Agreement) from $4.76 to $10.20.”

Vivakor, Inc. issued 500,000 shares of common stock to accredited investors for $19,750 of the amounts due.

“On December 8, 2025 and December 9, 2025, the Company received two Notices of Conversion from the Lenders converting $100,000 and $19,750 of the amounts due under the Lender Notes into 2,262,443 and 500,000 shares of the Company’s common stock (the “Lender Shares”), respectively.”

Vivakor, Inc. issued 2,262,443 shares of common stock to accredited investors for $100,000 of the amounts due.

“On December 8, 2025 and December 9, 2025, the Company received two Notices of Conversion from the Lenders converting $100,000 and $19,750 of the amounts due under the Lender Notes into 2,262,443 and 500,000 shares of the Company’s common stock (the “Lender Shares”), respectively.”

Vivakor, Inc. issued 964,954 shares of common stock to accredited investors for $45,738.82 of the principal amount and interest.

“On December 4, 2025, the Company received a Notice of Conversion (the "Holder’s Notice of Conversion") from one of the Holders converting an aggregate of $45,738.82 of the principal amount and interest due under the Notes into 964,954 shares of the Company’s common stock (the “Holder’s Shares”).”

Golub Capital BDC 4, Inc. issued 6,337,944.133 shares of common stock to stockholders (accredited investors) for aggregate offering price of $95.07 million.

“On December 4, 2025, Golub Capital BDC 4, Inc. (the “Company”) delivered a capital drawdown notice to its stockholders relating to the sale of 6,337,944.133 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), for an aggregate offering price of $95.07 million.”

Brag House Holdings, Inc. issued convertible note to institutional investor for aggregate original principal amount of up to $11,000,000.

“Company and HOD, jointly and severally, authorized the issuance of a convertible promissory note to the Investor, in the aggregate original principal amount of up to $11,000,000 (the “ Convertible Note ”)”

Brag House Holdings, Inc. issued up to the lesser of (a) $100,000,000 in aggregate gross purchase price of newly issued shares of the Company’s common stock (the "Equity Line Securities") and ( of common stock to institutional investor for 97% of the volume weighted average price of the Securities (the "VWAP").

“price that the Investor is required to pay for the Equity Line Securities in a Purchase effected by the Company pursuant to the Purchase Agreement, if any, will be equal to 97% of the volume weighted average price of the Securities (the “ VWAP ”), calculated in accordance with the Purchase Agreement, during the applicable Purchase Date (the “”

Liberty Media Corp issued 47,297 shares of FWONB of common stock to John C. Malone for shares of FWONK.

“on December 8, 2025, the JM Trust transferred to the Company an aggregate of 47,297 shares of FWONB and in exchange, the Company issued to the JM Trust an equivalent number of shares of the Company's Series C Liberty Formula One common stock, par value $0.01 per share (" FWONK ").”

Moleculin Biotech, Inc. issued 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823 of warrant to holders of existing Series C warrants, Series D warrants and Series F warrants for aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants.

“registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $6.63 per share, will be”

Crypto Co issued convertible note to Eksa Holdings LLC, Practivist Investors LLC, and Robert Nail for additional consideration for entering into Conversion Agreements.

“As additional consideration for the Investors’ to enter into the Conversion Agreements, the Company issued to each Investor a new Promissory Note in the original principal amount of each Investor’s Original Note (each a “ Promissory Note ” and collectively, the “ Promissory Notes ”).”

Crypto Co issued 713,915,563 shares of the Company’s common stock of warrant to AJB Capital Investments LLC for part of the AJB Conversion Agreement consideration.

“In connection with the closing, the Company issued to AJB 476,953,697 shares of the Company’s common stock, par value $0.001 per share (the “ Conversion Shares ”), $500,000 in cash, and a pre-funded warrant to purchase up to 713,915,563 shares of the Company’s common stock (the “ Warrant ”).”

Crypto Co issued 476,953,697 shares of the Company’s common stock of common stock to AJB Capital Investments LLC for exchange for the conversion of a prior agreement, $500,000 cash, and a pre-funded warrant.

“On December 10, 2025, the Company consummated the closing of the previously announced AJB Conversion Agreement, as disclosed in the Company’s Form 8-K filed on December 3, 2025 with AJB Capital Investments LLC (“ AJB ”). In connection with the closing, the Company issued to AJB 476,953,697 shares of the Company’s common stock, par value $0.001 per share (the “ Conversion Shares ”), $500,000 in cash, and a pre-funded warrant to purchase up to 713,915,563 shares of the Company’s common stock (the “ Warrant ”).”

Crypto Co issued 271,136,940 shares of its common stock of common stock to Eksa Holdings LLC, Practivist Investors LLC, and Robert Nail for exchange for the early conversion of certain outstanding promissory notes from August 2025.

“On December 4 th and 5 th , 2025, the Crypto Company (the “ Company ”) entered into Conversion Agreements with Eksa Holdings LLC, Practivist Investors LLC, and Robert Nail (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company issued an aggregate of 271,136,940 shares of its common stock to the Investors (“ Shares ”) in exchange for the early conversion of certain outstanding promissory notes from August 2025 (the “ Original Notes ”) previously held by the Investors (the “ Conversion Agreements ”).”

FORUM MARKETS Inc issued 2,905,064 shares of its Series B-3 Preferred Stock of preferred stock to Zippy, Inc. for $5 million in cash; and 1,333,332 shares of our common stock with an agreed value of approximately $14 million, based on a price per share of $10.50.

“Pursuant to the Zippy Purchase Agreement, Zippy sold us 2,905,064 shares of its Series B-3 Preferred Stock (the “ Zippy Series B-3 Shares ”) representing 13.492% of Zippy’s fully-diluted capitalization in consideration for (a) $5 million in cash; and (b) 1,333,332 shares of our common stock (the “ Zippy Shares ”) with an agreed value of approximately $14 million, based on a price per share of $10.50 (the “ Per-Share Price ”).”

Cottonwood Communities, Inc. issued 187,057 shares of preferred stock to accredited investors for $10.00 per share, aggregate proceeds $1,805,000.

“During the period from November 28, 2025 through December 9, 2025, we issued and sold 187,057 shares of Series A Convertible Preferred Stock in the Series A Convertible Private Offering and received aggregate proceeds of $1,805,000.”

Momentus Inc. issued 240,000 shares of warrant to Space Infrastructures Ventures, LLC.

“the Company issued SIV warrants to purchase up to 240,000 shares of Common Stock at an exercise price of $0.79 per share”

Exodus Movement, Inc. issued securities.

“Certain rights of the Company’s stockholders were changed as a result of the Redomestication.”

CITIUS ONCOLOGY, INC. issued up to 1,155,963 shares of common stock of warrant to H.C. Wainwright and Co., LLC.

“In addition, the Company granted placement agent warrants to Wainwright, or its designees, to purchase up to 1,155,963 shares of common stock (the “Placement Agent Warrants”)”

CITIUS ONCOLOGY, INC. issued 15,229,358 Common Warrants of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock (the “Pre-funded Warrants”) and 15,229,358 Common Warrants, at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant”

CITIUS ONCOLOGY, INC. issued pre-funded warrants to purchase up to 15,229,358 shares of common stock of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“On December 8, 2025, the Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement”, together with the RD Purchase Agreement, the “Purchase Agreements”) with such institutional investor to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock (the “Pre-funded Warrants”) and 15,229,358 Common Warrants, at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant”

CITIUS ONCOLOGY, INC. issued warrants to purchase up to 1,284,404 shares of common stock of warrant to such institutional investor for at a combined price of $1.0899 per Pre-funded Warrant and accompanying Common Warrant.

“In a concurrent private placement, the Company also agreed to sell such institutional investor warrants to purchase up to 1,284,404 shares of common stock (the “Common Warrants”), with an exercise price of $1.09 per share of our common stock”

CITIUS ONCOLOGY, INC. issued 1,284,404 shares of common stock to a certain institutional investor for $1.09 per share.

“On December 8, 2025, Citius Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “RD Purchase Agreement”) with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock, $0.0001 par value per share, at an offering price of $1.09 per share of common stock”

West Bay BDC LLC issued approximately 1.6 million common units of common stock to accredited investors for aggregate offering price of approximately $27.8 million.

“On December 8, 2025, West Bay BDC LLC (the “Company”) delivered a capital drawdown notice to investors relating to the sale of approximately 1.6 million common units of the Company’s limited liability company interests (the “Common Units”) for an aggregate offering price of approximately $27.8 million.”

Oncotelic Therapeutics, Inc. issued Each Unit consists of one note in the principal amount of $25,000, convertible into up to 250,000 shares of Common Stock or 25,000 shares of EdgePoint Common St of unit to accredited investors for $25,000 per Unit, or exchange of 2023 PPM Note.

“On December 4, 2025, Oncotelic Therapeutics, Inc. (the “ Company ”) completed entering into subscription agreements with certain accredited investors (“ Subscription Agreement ”), whereby the Company issued a total of 11 units (“ Units ”).”

3D SYSTEMS CORP issued 16,625,243 shares of common stock to institutional accredited investors and qualified institutional buyers.

“Pursuant to the Exchange and Consent Agreements, the Company has agreed to exchange $30,773,000 aggregate principal amount of 2026 Notes held by the Transaction Participants for an aggregate of 16,625,243 shares (“Shares”) of the Company’s common stock, par value $0.001 per share”

Star Equity Holdings, Inc. issued 287,631 shares of common stock to Mr. Eberwein for 320,855 shares of Company 10.0% Series A Cumulative Perpetual Preferred Stock.

“On December 8, 2025, the Company entered into a securities exchange agreement with Mr. Eberwein (the “Securities Exchange Agreement”), pursuant to which Mr. Eberwein purchased from the Company, 287,631 shares (the “Purchased Shares”) of Company common stock, par value $0.001 per share, (“Common Stock”) at a purchase price per share of Common Stock of $10.43, equal to the consolidated closing bid price of the Common Stock. In exchange for the Purchased Shares, Mr. Eberwein transferred 320,855 shares of Company 10.0% Series A Cumulative Perpetual Preferred Stock, par value $0.001 per share (“Preferred Stock”) to the Company.”

Q/C TECHNOLOGIES, INC. issued 212,500 restricted shares of Common Stock of common stock to Ocean Avenue Holdings LLC.

“(iii) grant to the Consultant 212,500 restricted shares of Common Stock, which vest in four substantially equal installments on the quarterly anniversaries of the issuance date”